ASCO: With FDA review nearing, Epizyme shares updated sarcoma data

fiercebiotech | June 03, 2019

Epizyme has posted updated data from the phase 2 trial it hopes will secure tazemetostat approval in epithelioid sarcoma. The data feature a slight uptick in objective responses offset by rises in the rates of some adverse events.Massachusetts-based Epizyme filed for authorization of tazemetostat last week and arrived at the American Society of Clinical Oncology (ASCO) annual meeting armed with data it hopes will persuade the FDA to approve the EZH2 inhibitor. The ASCO data set features one more month of follow-up than the results shared by Epizyme at a previous cancer conference.

Spotlight

The digital patient has arrived! Thanks to innovative mobile technology and the prevalence of broadband networks, patients are investing in their own healthcare more than ever before. From searching for a physician online to tracking fitness activities via wearable technology to accessing their personal health records.

Spotlight

The digital patient has arrived! Thanks to innovative mobile technology and the prevalence of broadband networks, patients are investing in their own healthcare more than ever before. From searching for a physician online to tracking fitness activities via wearable technology to accessing their personal health records.

Related News

Bioclean Innovations and rep-l® Antimicrobials Partners to Launch a Powerful Non-toxic Bio-based Antimicrobial Product Line

Bioclean Innovations | October 19, 2020

Bioclean Innovations Inc, a Biotech startup focused on innovative antimicrobial solutions to combat disease outbreaks has partnered with rep-L® Antimicrobials, to launch a powerful but non-toxic bio-based antimicrobial product line. Our rep-L-based disinfectants are designed to create a new methodology for addressing the infection control challenges facing the education and long-term health care sectors today. The SARS-CoV-2 virus responsible for the COVID-19 pandemic is one of an increasing number of pathogens and antibiotic-resistant infections society is facing. Schools, universities, and care homes rely on a frequent cleaning and disinfection process which now requires more cleaning and disinfectant products and more labor while still leaving the risks of microbial transmission from contamination occurring on the surface in between disinfection cycles. Bioclean has developed a range of products, including continuously-active disinfectant, hand sanitizer, and disinfectant wipes that can kill and protect against viruses, bacteria, and fungi for thirty (30) days and longer, eliminating the need for frequent disinfection and providing effective, long-lasting protection on high touch surfaces and hands.

Read More

CELL AND GENE THERAPY

Mekonos Raises $4.6M Financing Round for Targeted Ex Vivo Gene Engineering

Mekonos | November 24, 2020

Mekonos, a biotech organization launching the first-of-its kind system-on-a-chip (SoC) for focused ex vivo gene engineering, today reported it has finished a $4.6 million financing round. Mekonos will utilize the new funding to quicken the SoC stage for its current and new ad organizations. The SoC stage, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The stage is versatile over all cell types and has demonstrated to be a high return answer for partners. The stage assists organizations with expanding limit, quicken revelations, and develop new pre-clinical assets in the emerging cell and gene therapy space. The financing round was driven by Novartis AG with participation from institutional VCs including Hike Ventures, CRCM Ventures. Existing investors participated in the round, including Good AI Capital and past lead Elementum Ventures.

Read More

MEDICAL

Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine

Novavax, Inc. | January 31, 2022

Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has submitted a request to the U.S Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for NVX-CoV2373, its protein-based COVID-19 vaccine candidate for immunization of individuals 18 year of age and older against SARS-CoV-2. The request for EUA is based on the totality of pre-clinical, clinical and manufacturing-related (CMC) data provided to the agency, including results of two large pivotal clinical trials that demonstrated an overall efficacy of approximately 90 percent and a reassuring safety profile. "We're extremely proud of the work of our teams and we look forward to FDA's review of our EUA request. We believe our vaccine offers a differentiated option built on a well-understood protein-based vaccine platform that can be an alternative to the portfolio of available vaccines to help fight the COVID-19 pandemic. I'd like to also extend our thanks for the support of the U.S. Department of Health and Human Services and the U.S. Department of Defense for their partnership leading up to today's milestone of EUA request submission." Stanley C. Erck, President and Chief Executive Officer, Novavax Novavax conducted two pivotal Phase 3 clinical trials: PREVENT-19 which enrolled approximately 30,000 participants in the U.S. and Mexico and published results in the New England Journal of Medicine (NEJM) and a trial with almost 15,000 participants in the U.K. which was also published in NEJM. In both trials, the vaccine demonstrated efficacy with a reassuring safety profile. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups. The most common adverse reactions observed during clinical studies (frequency category of very common ≥1/10) were headache, nausea or vomiting, myalgia, arthralgia, injection site tenderness/pain, fatigue, and malaise. Novavax will continue to collect and analyze real-world data, including the monitoring of safety and the evaluation of variants, as the vaccine is distributed in authorized markets. As part of the PREVENT-19 trial, a booster study is ongoing to evaluate the safety and effectiveness of a third does of the vaccine, as well as a study in adolescents aged 12-17. NVX-CoV2373 has been granted conditional authorization by multiple regulatory agencies worldwide, including the European Commission, and emergency use listing (EUL) from the World Health Organization (WHO), with additional filings currently under review. About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. Novavax' COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2°- 8° Celsius, enabling the use of existing vaccine supply and cold chain channels. Use of the vaccine should be in accordance with official recommendations. Novavax has established partnerships for the manufacture, commercialization and distribution of NVX-CoV2373 worldwide. Existing authorizations leverage Novavax' manufacturing partnership with Serum Institute of India (SII), the world's largest vaccine manufacturer by volume. They will later be supplemented with data from additional manufacturing sites throughout Novavax' global supply chain. About the NVX-CoV2373 Phase 3 trials NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials. PREVENT-19, a trial in the U.S. and Mexico that enrolled almost 30,000 participants, achieved 90.4% efficacy overall. It was designed as a 2:1 randomized, placebo-controlled, observer-blinded study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373. The primary endpoint for PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least 7 days after the second dose in serologically negative (to SARS-CoV-2) adult participants at baseline. The statistical success criterion included a lower bound of 95% CI >30%. The key secondary endpoint is the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Both endpoints were assessed at least seven days after the second study vaccination in volunteers who had not been previously infected with SARS-CoV-2. It was generally well-tolerated and elicited a robust antibody response after the second dose in both studies. Full results of the trial were published in the New England Journal of Medicine (NEJM). A trial conducted in the U.K. with 14,039 participants was designed as a randomized, placebo-controlled, observer-blinded study and achieved overall efficacy of 89.7%. The primary endpoint was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least 7 days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. Full results of the trial were published in NEJM. PREVENT-19 is being conducted with support from the U.S. government, including the Department of Defense, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at HHS. BARDA is providing up to $1.75 billion under a Department of Defense agreement. About Matrix-M™ Adjuvant Novavax' patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and generally well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response. About Novavax Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, received Conditional Marketing Authorization from the European Commission, Emergency Use Listing from the World Health Organization, Emergency Use Authorization in Indonesia and the Philippines, and has been submitted for regulatory authorization in multiple markets globally.

Read More